Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Cost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares OutstandingShares Outstanding
Ratios

Bioregenx (BRGX) Gross Profit (2023 - 2025)

Bioregenx has reported Gross Profit over the past 3 years, most recently at $318775.0 for Q4 2025.

  • For Q4 2025, Gross Profit fell 1.23% year-over-year to $318775.0; the TTM value through Dec 2025 reached $1.5 million, down 9.33%, while the annual FY2025 figure was $1.5 million, 9.33% down from the prior year.
  • Gross Profit for Q4 2025 was $318775.0 at Bioregenx, down from $426397.0 in the prior quarter.
  • Over five years, Gross Profit peaked at $763891.0 in Q1 2023 and troughed at $318775.0 in Q4 2025.
  • A 3-year average of $456125.7 and a median of $416214.0 in 2025 define the central range for Gross Profit.
  • Biggest five-year swings in Gross Profit: crashed 49.71% in 2024 and later rose 5.69% in 2025.
  • Year by year, Gross Profit stood at $378025.0 in 2023, then dropped by 14.63% to $322737.0 in 2024, then dropped by 1.23% to $318775.0 in 2025.
  • Business Quant data shows Gross Profit for BRGX at $318775.0 in Q4 2025, $426397.0 in Q3 2025, and $352456.0 in Q2 2025.